{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T02:49:49Z","timestamp":1789008589740,"version":"build-2803163510"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T00:00:00Z","timestamp":1702598400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T00:00:00Z","timestamp":1702598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s40263-023-01058-9","type":"journal-article","created":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T14:02:22Z","timestamp":1702648942000},"page":"1-14","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Effect of Levetiracetam on Cognition: A Systematic Review and Meta-analysis of Double-Blind Randomized Placebo-Controlled Trials"],"prefix":"10.1007","volume":"38","author":[{"given":"Chia-Yen","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Chia","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3304-4643","authenticated-orcid":false,"given":"Hong-Jie","family":"Jhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,15]]},"reference":[{"issue":"26","key":"1058_CR1","doi-asserted-by":"publisher","first-page":"9861","DOI":"10.1073\/pnas.0308208101","volume":"101","author":"BA Lynch","year":"2004","unstructured":"Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA. 2004;101(26):9861\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"1058_CR2","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1097\/WNR.0000000000000601","volume":"27","author":"S Sanz-Blasco","year":"2016","unstructured":"Sanz-Blasco S, Pi\u00f1a-Crespo JC, Zhang X, McKercher SR, Lipton SA. Levetiracetam inhibits oligomeric A\u03b2-induced glutamate release from human astrocytes. NeuroReport. 2016;27(9):705\u20139.","journal-title":"NeuroReport"},{"issue":"42","key":"1058_CR3","doi-asserted-by":"publisher","first-page":"E2895","DOI":"10.1073\/pnas.1121081109","volume":"109","author":"PE Sanchez","year":"2012","unstructured":"Sanchez PE, Zhu L, Verret L, Vossel KA, Orr AG, Cirrito JR, et al. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer\u2019s disease model. Proc Natl Acad Sci. 2012;109(42):E2895\u2013903.","journal-title":"Proc Natl Acad Sci"},{"issue":"8","key":"1058_CR4","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/s41582-021-00505-9","volume":"17","author":"M Romoli","year":"2021","unstructured":"Romoli M, Sen A, Parnetti L, Calabresi P, Costa C. Amyloid-\u03b2: a potential link between epilepsy and cognitive decline. Nat Rev Neurol. 2021;17(8):469\u201385.","journal-title":"Nat Rev Neurol"},{"key":"1058_CR5","doi-asserted-by":"crossref","unstructured":"Liu J, Wang LN. Treatment of epilepsy for people with Alzheimer's disease. Cochrane Database Syst Rev. 2021;5(5):CD011922.","DOI":"10.1002\/14651858.CD011922.pub4"},{"issue":"2","key":"1058_CR6","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.yebeh.2007.10.003","volume":"12","author":"B Zhou","year":"2008","unstructured":"Zhou B, Zhang Q, Tian L, Xiao J, Stefan H, Zhou D. Effects of levetiracetam as an add-on therapy on cognitive function and quality of life in patients with refractory partial seizures. Epilepsy Behav. 2008;12(2):305\u201310.","journal-title":"Epilepsy Behav"},{"issue":"9","key":"1058_CR7","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1111\/epi.13849","volume":"58","author":"MR Schoenberg","year":"2017","unstructured":"Schoenberg MR, Rum RS, Osborn KE, Werz MA. A randomized, double-blind, placebo-controlled crossover study of the effects of levetiracetam on cognition, mood, and balance in healthy older adults. Epilepsia. 2017;58(9):1566\u201374.","journal-title":"Epilepsia"},{"issue":"4","key":"1058_CR8","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1097\/YIC.0000000000000405","volume":"37","author":"F Behdani","year":"2022","unstructured":"Behdani F, Hassanzadeh B, Eslamzadeh M, Moradi M, Hebrani P, Dadgarmoghaddam M, et al. Can levetiracetam improve clinical symptoms in schizophrenic patients? A randomized placebo-controlled clinical trial. Int Clin Psychopharmacol. 2022;37(4):159\u201365.","journal-title":"Int Clin Psychopharmacol"},{"issue":"6","key":"1058_CR9","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1177\/0269881109359095","volume":"25","author":"DE Feltner","year":"2011","unstructured":"Feltner DE, Haig G. Evaluation of the subjective and reinforcing effects of diphenhydramine, levetiracetam, and valproic acid. J Psychopharmacol. 2011;25(6):763\u201373.","journal-title":"J Psychopharmacol"},{"issue":"11","key":"1058_CR10","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1345\/aph.1E136","volume":"38","author":"O Mecarelli","year":"2004","unstructured":"Mecarelli O, Vicenzini E, Pulitano P, Vanacore N, Romolo FS, Di Piero V, et al. Clinical, cognitive, and neurophysiologic correlates of short-term treatment with carbamazepine, oxcarbazepine, and levetiracetam in healthy volunteers. Ann Pharmacother. 2004;38(11):1816\u201322.","journal-title":"Ann Pharmacother"},{"issue":"11","key":"1058_CR11","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1111\/j.1528-1167.2009.02197.x","volume":"50","author":"PM Levisohn","year":"2009","unstructured":"Levisohn PM, Mintz M, Hunter SJ, Yang H, Jones J. Neurocognitive effects of adjunctive levetiracetam in children with partial-onset seizures: a randomized, double-blind, placebo-controlled, noninferiority trial. Epilepsia. 2009;50(11):2377\u201389.","journal-title":"Epilepsia"},{"issue":"7","key":"1058_CR12","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.eurpsy.2007.06.002","volume":"22","author":"ES Brown","year":"2007","unstructured":"Brown ES, Frol AB, Khan DA, Larkin GL, Bret ME. Impact of levetiracetam on mood and cognition during prednisone therapy. Eur Psychiatry. 2007;22(7):448\u201352.","journal-title":"Eur Psychiatry"},{"key":"1058_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71.","journal-title":"BMJ"},{"key":"1058_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.883251","volume":"13","author":"IC Tsai","year":"2022","unstructured":"Tsai IC, Hsu CW, Chang CH, Tseng PT, Chang KV. Effectiveness of coenzyme Q10 supplementation for reducing fatigue: a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 2022;13: 883251.","journal-title":"Front Pharmacol"},{"issue":"1","key":"1058_CR15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13643-021-01877-1","volume":"11","author":"D Pieper","year":"2022","unstructured":"Pieper D, Rombey T. Where to prospectively register a systematic review. Syst Rev. 2022;11(1):8.","journal-title":"Syst Rev"},{"key":"1058_CR16","unstructured":"HJ LCCMJ. The effect of levetiracetam on cognition, a systemic review and meta-analysis of the double-blinded randomized placebo-controlled trials. 2023."},{"key":"1058_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366: l4898.","journal-title":"BMJ"},{"key":"1058_CR18","unstructured":"Deeks JJ HJ, Altman DG. Chapter 10: Analysing data and undertaking meta-analyses. Cochrane Handbook for Systematic Reviews of Interventions version 63. 2022."},{"issue":"1","key":"1058_CR19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1471-2288-5-13","volume":"5","author":"SP Hozo","year":"2005","unstructured":"Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Research Methodol. 2005;5(1):13.","journal-title":"BMC Med Research Methodol."},{"key":"1058_CR20","unstructured":"Higgins JPT ES, Li T Chapter 23: Including variants on randomized trials. Cochrane Handbook for Systematic Reviews of Interventions version 63. 2022."},{"key":"1058_CR21","unstructured":"Higgins JPT LT, Deeks JJ. Chapter 6: Choosing effect measures and computing estimates of effect. Cochrane Handbook for Systematic Reviews of Interventions version 63. 2022."},{"key":"1058_CR22","doi-asserted-by":"crossref","unstructured":"Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Fixed-effect versus random-effects models. Introduction to meta\u2010analysis; 2009. p. 77\u201386.","DOI":"10.1002\/9780470743386.ch13"},{"issue":"7414","key":"1058_CR23","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360.","journal-title":"BMJ"},{"key":"1058_CR24","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.nicl.2015.02.009","volume":"7","author":"A Bakker","year":"2015","unstructured":"Bakker A, Albert MS, Krauss G, Speck CL, Gallagher M. Response of the medial temporal lobe network in amnestic mild cognitive impairment to therapeutic intervention assessed by fMRI and memory task performance. Neuroimage Clin. 2015;7:688\u201398.","journal-title":"Neuroimage Clin."},{"issue":"3","key":"1058_CR25","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.neuron.2012.03.023","volume":"74","author":"A Bakker","year":"2012","unstructured":"Bakker A, Krauss GL, Albert MS, Speck CL, Jones LR, Stark CE, et al. Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment. Neuron. 2012;74(3):467\u201374.","journal-title":"Neuron"},{"issue":"1","key":"1058_CR26","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.yebeh.2012.12.007","volume":"27","author":"H Bj\u00f8rn\u00e6s","year":"2013","unstructured":"Bj\u00f8rn\u00e6s H, Bakke KA, Larsson PG, Heminghyt E, Rytter E, Brager-Larsen LM, et al. Subclinical epileptiform activity in children with electrical status epilepticus during sleep: effects on cognition and behavior before and after treatment with levetiracetam. Epilepsy Behav. 2013;27(1):40\u20138.","journal-title":"Epilepsy Behav"},{"issue":"2","key":"1058_CR27","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/j.1528-1167.2010.02746.x","volume":"52","author":"KJ Meador","year":"2011","unstructured":"Meador KJ, Gevins A, Leese PT, Otoul C, Loring DW. Neurocognitive effects of brivaracetam, levetiracetam, and lorazepam. Epilepsia. 2011;52(2):264\u201372.","journal-title":"Epilepsia"},{"issue":"1","key":"1058_CR28","doi-asserted-by":"publisher","first-page":"83","DOI":"10.9758\/cpn.2015.13.1.83","volume":"13","author":"JC Magalh\u00e3es","year":"2015","unstructured":"Magalh\u00e3es JC, Gongora M, Vicente R, Bittencourt J, Tanaka G, Velasques B, et al. The influence of levetiracetam in cognitive performance in healthy individuals: neuropsychological, behavioral and electrophysiological approach. Clin Psychopharmacol Neurosci. 2015;13(1):83\u201393.","journal-title":"Clin Psychopharmacol Neurosci."},{"issue":"1","key":"1058_CR29","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1097\/JCP.0000000000000246","volume":"35","author":"CM Knapp","year":"2015","unstructured":"Knapp CM, Ciraulo DA, Sarid-Segal O, Richardson MA, Devine E, Streeter CC, et al. Zonisamide, topiramate, and levetiracetam: efficacy and neuropsychological effects in alcohol use disorders. J Clin Psychopharmacol. 2015;35(1):34\u201342.","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"1058_CR30","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.3233\/JAD-160742","volume":"58","author":"CS Musaeus","year":"2017","unstructured":"Musaeus CS, Shafi MM, Santarnecchi E, Herman ST, Press DZ. Levetiracetam alters oscillatory connectivity in Alzheimer\u2019s disease. J Alzheimers Dis. 2017;58(4):1065\u201376.","journal-title":"J Alzheimers Dis"},{"issue":"11","key":"1058_CR31","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1001\/jamaneurol.2021.3310","volume":"78","author":"K Vossel","year":"2021","unstructured":"Vossel K, Ranasinghe KG, Beagle AJ, La A, Ah Pook K, Castro M, et al. Effect of levetiracetam on cognition in patients with alzheimer disease with and without epileptiform activity: a randomized clinical trial. JAMA Neurol. 2021;78(11):1345\u201354.","journal-title":"JAMA Neurol"},{"issue":"3","key":"1058_CR32","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1159\/000520457","volume":"81","author":"A Keshavarzi","year":"2022","unstructured":"Keshavarzi A, Sharifi A, Jahangard L, Soltanian A, Br\u00fchl AB, Ahmadpanah M, et al. Levetiracetam as an adjunctive treatment for mania: a double-blind, randomized, placebo-controlled trial. Neuropsychobiology. 2022;81(3):192\u2013203.","journal-title":"Neuropsychobiology"},{"key":"1058_CR33","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1146\/annurev-psych-113011-143750","volume":"64","author":"A Diamond","year":"2013","unstructured":"Diamond A. Executive functions. Annu Rev Psychol. 2013;64:135\u201368.","journal-title":"Annu Rev Psychol"},{"issue":"4","key":"1058_CR34","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.cger.2013.07.002","volume":"29","author":"CN Harada","year":"2013","unstructured":"Harada CN, Natelson Love MC, Triebel KL. Normal cognitive aging. Clin Geriatr Med. 2013;29(4):737\u201352.","journal-title":"Clin Geriatr Med"},{"issue":"3","key":"1058_CR35","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1176\/appi.psy.44.3.204","volume":"44","author":"ES Brown","year":"2003","unstructured":"Brown ES, Frol A, Bobadilla L, Nejtek VA, Perantie DC, Dhillon H. Effect of lamotrigine on mood and cognition in patients receiving chronic exogenous corticosteroids. Psychosomatics. 2003;44(3):204\u20138.","journal-title":"Psychosomatics"},{"issue":"1","key":"1058_CR36","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.addbeh.2013.09.032","volume":"39","author":"RJ Houston","year":"2014","unstructured":"Houston RJ, Derrick JL, Leonard KE, Testa M, Quigley BM, Kubiak A. Effects of heavy drinking on executive cognitive functioning in a community sample. Addict Behav. 2014;39(1):345\u20139.","journal-title":"Addict Behav"},{"issue":"3","key":"1058_CR37","doi-asserted-by":"publisher","first-page":"227","DOI":"10.31887\/DCNS.2019.21.3\/pharvey","volume":"21","author":"PD Harvey","year":"2019","unstructured":"Harvey PD. Domains of cognition and their assessment. Dialog Clin Neurosci. 2019;21(3):227\u201337.","journal-title":"Dialog Clin Neurosci"},{"key":"1058_CR38","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.neubiorev.2018.05.008","volume":"92","author":"EJ Bubb","year":"2018","unstructured":"Bubb EJ, Metzler-Baddeley C, Aggleton JP. The cingulum bundle: anatomy, function, and dysfunction. Neurosci Biobehav Rev. 2018;92:104\u201327.","journal-title":"Neurosci Biobehav Rev"},{"issue":"2","key":"1058_CR39","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1034\/j.1600-0404.2003.02067.x","volume":"108","author":"CJ Stam","year":"2003","unstructured":"Stam CJ, van der Made Y, Pijnenburg YA, Scheltens P. EEG synchronization in mild cognitive impairment and Alzheimer\u2019s disease. Acta Neurol Scand. 2003;108(2):90\u20136.","journal-title":"Acta Neurol Scand"},{"issue":"4","key":"1058_CR40","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3390\/ph15040475","volume":"15","author":"IJ Contreras-Garc\u00eda","year":"2022","unstructured":"Contreras-Garc\u00eda IJ, C\u00e1rdenas-Rodr\u00edguez N, Romo-Mancillas A, Bandala C, Zamudio SR, G\u00f3mez-Manzo S, et al. Levetiracetam mechanisms of action: from molecules to systems. Pharmaceuticals (Basel). 2022;15(4):475.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"4","key":"1058_CR41","doi-asserted-by":"publisher","first-page":"178","DOI":"10.3988\/jcn.2009.5.4.178","volume":"5","author":"SP Park","year":"2009","unstructured":"Park SP, Kwon OY. Increased EEG current-source density in the high Beta frequency band induced by levetiracetam adjunctive therapy in refractory partial epilepsy. J Clin Neurol. 2009;5(4):178\u201385.","journal-title":"J Clin Neurol"},{"issue":"4","key":"1058_CR42","first-page":"489","volume":"71","author":"KA Lyseng-Williamson","year":"2011","unstructured":"Lyseng-Williamson KA. Levetiracetam: a review of its use in epilepsy. Drugs. 2011;71(4):489\u2013514.","journal-title":"Drugs"},{"issue":"7","key":"1058_CR43","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","volume":"49","author":"PN Patsalos","year":"2008","unstructured":"Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, Johannessen SI, et al. Antiepileptic drugs\u2014best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE commission on therapeutic strategies. Epilepsia. 2008;49(7):1239\u201376.","journal-title":"Epilepsia"},{"issue":"4","key":"1058_CR44","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1038\/npp.2009.207","volume":"35","author":"MT Koh","year":"2010","unstructured":"Koh MT, Haberman RP, Foti S, McCown TJ, Gallagher M. Treatment strategies targeting excess hippocampal activity benefit aged rats with cognitive impairment. Neuropsychopharmacology. 2010;35(4):1016\u201325.","journal-title":"Neuropsychopharmacology"},{"key":"1058_CR45","doi-asserted-by":"crossref","unstructured":"Diaz-Orueta U, Rogers BM, Blanco-Campal A, Burke T. The challenge of neuropsychological assessment of visual\/visuo-spatial memory: a critical, historical review, and lessons for the present and future. Front Psychol. 2022;13.","DOI":"10.3389\/fpsyg.2022.962025"},{"issue":"3","key":"1058_CR46","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1016\/j.neuroimage.2010.03.040","volume":"51","author":"MA Yassa","year":"2010","unstructured":"Yassa MA, Stark SM, Bakker A, Albert MS, Gallagher M, Stark CE. High-resolution structural and functional MRI of hippocampal CA3 and dentate gyrus in patients with amnestic mild cognitive impairment. Neuroimage. 2010;51(3):1242\u201352.","journal-title":"Neuroimage"},{"issue":"6","key":"1058_CR47","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1101\/lm.1768110","volume":"17","author":"SM Stark","year":"2010","unstructured":"Stark SM, Yassa MA, Stark CE. Individual differences in spatial pattern separation performance associated with healthy aging in humans. Learn Mem. 2010;17(6):284\u20138.","journal-title":"Learn Mem"},{"issue":"7","key":"1058_CR48","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1056\/NEJMra041071","volume":"352","author":"AE Budson","year":"2005","unstructured":"Budson AE, Price BH. Memory dysfunction. N Engl J Med. 2005;352(7):692\u20139.","journal-title":"N Engl J Med"},{"issue":"1","key":"1058_CR49","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/nn988","volume":"6","author":"EA Maguire","year":"2003","unstructured":"Maguire EA, Valentine ER, Wilding JM, Kapur N. Routes to remembering: the brains behind superior memory. Nat Neuro. 2003;6(1):90\u20135.","journal-title":"Nat Neuro"},{"key":"1058_CR50","first-page":"S87","volume":"9","author":"SJ Li","year":"2022","unstructured":"Li SJ, Bakker A, Ward BD, Wang Y, Schold S, Antuono P, et al. LilyPADD trial: targeting hippocampal hyperconnectivity in cognitively normal older adults at risk for Alzheimer\u2019s disease with AGB101. J Prev Alzheimer\u2019s Dis. 2022;9:S87\u20138.","journal-title":"J Prev Alzheimer\u2019s Dis."},{"issue":"1","key":"1058_CR51","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1186\/s13063-021-05404-4","volume":"22","author":"A Sen","year":"2021","unstructured":"Sen A, Akinola M, Tai XY, Symmonds M, Davis Jones G, Mura S, et al. An Investigation of Levetiracetam in Alzheimer\u2019s Disease (ILiAD): a double-blind, placebo-controlled, randomised crossover proof of concept study. Trials. 2021;22(1):508.","journal-title":"Trials"},{"key":"1058_CR52","doi-asserted-by":"crossref","unstructured":"Rosenzweig-Lipson S, Barton R, Gallagher M, Mohs R. HOPE4MCI trial: first trial targeting reduction of hippocampal overactivity to treat mild cognitive impairment due to Alzheimer\u2019s disease with AGB101. Alzheimers Dement. 2021;17(S9).","DOI":"10.1002\/alz.057813"},{"key":"1058_CR53","unstructured":"Timothy R, Malone M. Levetiracetam for Alzheimer\u2019s disease neuropsychiatric symptoms related to epilepsy trial (LAPSE)\u2014a phase II exploratory study. 2019."},{"issue":"5","key":"1058_CR54","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.seizure.2007.12.003","volume":"17","author":"G Zaccara","year":"2008","unstructured":"Zaccara G, Gangemi PF, Cincotta M. Central nervous system adverse effects of new antiepileptic drugs. A meta-analysis of placebo-controlled studies. Seizure. 2008;17(5):405\u201321.","journal-title":"Seizure."},{"key":"1058_CR55","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.seizure.2018.07.017","volume":"61","author":"M Hirsch","year":"2018","unstructured":"Hirsch M, Hintz M, Specht A, Schulze-Bonhage A. Tolerability, efficacy and retention rate of Brivaracetam in patients previously treated with Levetiracetam: a monocenter retrospective outcome analysis. Seizure. 2018;61:98\u2013103.","journal-title":"Seizure."},{"issue":"1","key":"1058_CR56","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S1059-1311(03)00111-0","volume":"13","author":"M Mula","year":"2004","unstructured":"Mula M, Trimble MR, Sander JW. Psychiatric adverse events in patients with epilepsy and learning disabilities taking levetiracetam. Seizure. 2004;13(1):55\u20137.","journal-title":"Seizure."},{"issue":"5","key":"1058_CR57","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.yebeh.2003.07.008","volume":"4","author":"V Dinkelacker","year":"2003","unstructured":"Dinkelacker V, Dietl T, Widman G, Lengler U, Elger CE. Aggressive behavior of epilepsy patients in the course of levetiracetam add-on therapy: report of 33 mild to severe cases. Epilepsy Behav. 2003;4(5):537\u201347.","journal-title":"Epilepsy Behav"},{"issue":"2","key":"1058_CR58","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/S1525-5050(03)00005-2","volume":"4","author":"JA Cramer","year":"2003","unstructured":"Cramer JA, De Rue K, Devinsky O, Edrich P, Trimble MR. A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials. Epilepsy Behav. 2003;4(2):124\u201332.","journal-title":"Epilepsy Behav"},{"issue":"1","key":"1058_CR59","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.yebeh.2012.02.024","volume":"24","author":"PG Larsson","year":"2012","unstructured":"Larsson PG, Bakke KA, Bj\u00f8rn\u00e6s H, Heminghyt E, Rytter E, Brager-Larsen L, et al. The effect of levetiracetam on focal nocturnal epileptiform activity during sleep\u2014a placebo-controlled double-blind cross-over study. Epilepsy Behav. 2012;24(1):44\u20138.","journal-title":"Epilepsy Behav"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-023-01058-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-023-01058-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-023-01058-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T13:09:45Z","timestamp":1706188185000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-023-01058-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,15]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["1058"],"URL":"https:\/\/doi.org\/10.1007\/s40263-023-01058-9","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,15]]},"assertion":[{"value":"27 November 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no funding received.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare no financial or non-financial conflicts of interest related to this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interests"}},{"value":"As a secondary analysis of publicly available data, this study did not require approval from an ethics review board.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets generated during and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Chia-Yen Lin conceptualized the article, curated the data, developed the methodology, performed the formal analysis, managed the project, validated findings, and authored the initial draft. Meng-Chia Chang engaged in methodology development discussions and reviewed the manuscript. Hong-Jie Jhou collected data, contributed to the investigation, assisted in methodology formulation, validated results, and participated in manuscript review and editing. All authors have approved the manuscript and accept responsibility for its contents.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author\u2019s contributions"}}]}}